[
  {
    "ts": null,
    "headline": "Reasons Why Hedge Funds Favor Insulet Corp (PODD)",
    "summary": "Insulet Corporation (NASDAQ:PODD) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds. As of the close of play on January 28, Insulet Corporation (NASDAQ:PODD) carried a highly bullish consensus view. The stock received coverage from 18 analysts and was assigned 16 Buy ratings and 1 Hold rating. With […]",
    "url": "https://finnhub.io/api/news?id=f360c4b90fd1acf7af37bae9dc73112bba4fe5ea3c050a35d4de567ce3ad7631",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769801502,
      "headline": "Reasons Why Hedge Funds Favor Insulet Corp (PODD)",
      "id": 138309074,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PODD",
      "source": "Yahoo",
      "summary": "Insulet Corporation (NASDAQ:PODD) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds. As of the close of play on January 28, Insulet Corporation (NASDAQ:PODD) carried a highly bullish consensus view. The stock received coverage from 18 analysts and was assigned 16 Buy ratings and 1 Hold rating. With […]",
      "url": "https://finnhub.io/api/news?id=f360c4b90fd1acf7af37bae9dc73112bba4fe5ea3c050a35d4de567ce3ad7631"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Insulet (PODD) Valuation After Recent Share Price Weakness And Growth Expectations",
    "summary": "Insulet (PODD) is back on investors’ radar after recent trading pressure, with the share price showing declines over the past week, month and past 3 months that contrast with its underlying business metrics. See our latest analysis for Insulet. While Insulet’s 1 day share price return of 1.20% and 7 day share price return of 6.08% have been weak, the 1 year total shareholder return of 8.36% and 5 year total shareholder return of 9.27% point to a mixed picture where short term momentum has...",
    "url": "https://finnhub.io/api/news?id=38a960b46b92ea700311f0fecce44725d3af7c08eaf6b7f206cdc35a14de2025",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769796731,
      "headline": "Assessing Insulet (PODD) Valuation After Recent Share Price Weakness And Growth Expectations",
      "id": 138309075,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PODD",
      "source": "Yahoo",
      "summary": "Insulet (PODD) is back on investors’ radar after recent trading pressure, with the share price showing declines over the past week, month and past 3 months that contrast with its underlying business metrics. See our latest analysis for Insulet. While Insulet’s 1 day share price return of 1.20% and 7 day share price return of 6.08% have been weak, the 1 year total shareholder return of 8.36% and 5 year total shareholder return of 9.27% point to a mixed picture where short term momentum has...",
      "url": "https://finnhub.io/api/news?id=38a960b46b92ea700311f0fecce44725d3af7c08eaf6b7f206cdc35a14de2025"
    }
  },
  {
    "ts": null,
    "headline": "Is It Time To Reassess Insulet (PODD) After Recent Share Price Weakness",
    "summary": "If you are wondering whether Insulet is offering fair value at its current share price, you are not alone in asking what the market is really pricing in. The stock recently closed at US$255.10, with returns of a 6.1% decline over 7 days, a 10.3% decline over 30 days, and a 9.8% decline year to date, which may have shifted how some investors see its risk and reward trade off. Recent coverage of Insulet has focused on its role in the diabetes care space and how the company is positioned within...",
    "url": "https://finnhub.io/api/news?id=53592bb41d94172ed263d22f44c3018541b3d705924b8620c4e48974ddd3ebf0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769793192,
      "headline": "Is It Time To Reassess Insulet (PODD) After Recent Share Price Weakness",
      "id": 138307601,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PODD",
      "source": "Yahoo",
      "summary": "If you are wondering whether Insulet is offering fair value at its current share price, you are not alone in asking what the market is really pricing in. The stock recently closed at US$255.10, with returns of a 6.1% decline over 7 days, a 10.3% decline over 30 days, and a 9.8% decline year to date, which may have shifted how some investors see its risk and reward trade off. Recent coverage of Insulet has focused on its role in the diabetes care space and how the company is positioned within...",
      "url": "https://finnhub.io/api/news?id=53592bb41d94172ed263d22f44c3018541b3d705924b8620c4e48974ddd3ebf0"
    }
  }
]